Abstract
Focal therapy modalities achieved interest in the management of prostate cancer (PCa) over the last a few years. This systematic review was aimed to investigate erectile function after focal therapy for localized PCa. Twenty-six out of 1287 reports were identified through a database systematic search in MEDLINE, EMBASE, and Web of Science, supplemented with hand search, on June 1st, 2020, according to PRISMA guidelines. Focal therapy modalities investigated were cryotherapy, high-intensity focused ultrasound (HIFU), photodynamic therapy (TOOKAD), irreversible electroporation (IRE), and focal radiotherapy (RT) (i.e. brachytherapy or stereotactic RT). Overall, reported sexual function outcomes after these treatment modalities were generally good, with many studies reporting a complete recovery of EF at 1-year follow-up. However, the quality of current evidence is affected both by the lack of well-conducted comparative studies and by a significant heterogeneity in terms of study design, study population, erectile and sexual function assessment modalities.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA. 2014;311:1143–9.
Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203–13.
Sheets NC, Goldin GH, Meyer A-M, Wu Y, Chang Y, Stürmer T, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307:1611.
Mottet N, Bergh RCN van den, Briers E, Cornford P, Santis MD, Fanti S et al. EAU–EANM–ESTRO–ESUR–SIOG Guidelines on Prostate Cancer 2020. In: Office EG (ed). EAU Guidelines Office: Arnhem, The Netherlands, n.d. http://uroweb.org/guidelines/compilations-of-all-guidelines/prostate-cancer.
Moschini M, Carroll PR, Eggener SE, Epstein JI, Graefen M, Montironi R, et al. Low-risk prostate cancer: identification, management, and outcomes. Eur Urol. 2017;72:238–49.
Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol. 2014;66:732–51.
Lindner U, Trachtenberg J, Lawrentschuk N. Focal therapy in prostate cancer: modalities, findings and future considerations. Nat Rev Urol. 2010;7:562–71.
Lovegrove CC, Ficarra V, Montorsi F, N’Dow J, Salonia A, Minhas S. Sexual function outcomes following interventions for prostate cancer: are contemporary reports on functional outcomes misleading? Int J Impot Res. 2020;32:495–502.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700–b2700.
Izadifar Z, Izadifar Z, Chapman D, Babyn P. An introduction to high intensity focused ultrasound: systematic review on principles, devices, and clinical applications. J Clin Med. 2020;9:460.
Ahmed HU, Freeman A, Kirkham A, Sahu M, Scott R, Allen C, et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol. 2011;185:1246–54.
Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012;13:622–32.
Ahmed HU, Dickinson L, Charman S, Weir S, McCartan N, Hindley RG, et al. Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol. 2015;68:927–36.
Rischmann P, Gelet A, Riche B, Villers A, Pasticier G, Bondil P, et al. Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients. Eur Urol. 2016;71:267–73.
Albisinni S, Aoun F, Bellucci S, Biaou I, Limani K, Hawaux E, et al. Comparing high-intensity focal ultrasound hemiablation to robotic radical prostatectomy in the management of unilateral prostate cancer: a matched-pair analysis. J Endourol. 2017;31:14–9.
Hardenberg J, von, Westhoff N, Baumunk D, Hausmann D, Martini T, Marx A, et al. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: a prospective evaluation. Urol Oncol. 2018;36:401. e1-401. e9
Johnston MJ, Emara A, Noureldin M, Bott S, Hindley RG. Focal high-intensity focussed ultrasound partial gland ablation for the treatment of localised prostate cancer: a report of medium-term outcomes from a single-centre in the United Kingdom. Urology. 2019;133:175–81.
Lei Y, Zanker P, Yildiz S, Hancke K, Seidl D, Koch O, et al. Non-whole-gland high-intensity focused ultrasound vs whole-gland high-intensity focused ultrasound for management of localized prostate cancer: 1-year oncological and functional outcomes. J Endourol. 2019;33:100–6.
Linares-Espinós E, Carneiro A, Martínez-Salamanca JI, Bianco F, Castro-Alfaro A, Cathelineau X et al. New technologies and techniques for prostate cancer focal therapy: a review of the current literature. Italian J Urol Nephrol. 2018. https://doi.org/10.23736/s0393-2249.18.03094-1.
Azzouzi A-R, Vincendeau S, Barret E, Cicco A, Kleinclauss F, Poel HGvander, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2017;18:181–91.
Gill IS, Azzouzi A-R, Emberton M, Coleman JA, Coeytaux E, Scherz A, et al. Randomized trial of partial gland ablation with vascular targeted phototherapy versus active surveillance for low risk prostate cancer: extended followup and analyses of effectiveness. J Urol. 2018;200:786–93.
Wang L, Yang H, Li B. Photodynamic therapy for prostate cancer: a systematic review and meta-analysis. Prostate Int. 2019;7:83–90.
Moore CM, Azzouzi A-R, Barret E, Villers A, Muir GH, Barber NJ, et al. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy. BJU Int. 2015;116:888–96.
Azzouzi AR, Barret E, Bennet J, Moore C, Taneja S, Muir G, et al. TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. World J Urol. 2015;33:945–53.
Noweski A, Roosen A, Lebdai S, Barret E, Emberton M, Benzaghou F, et al. Medium-term follow-up of vascular-targeted photodynamic therapy of localized prostate cancer using TOOKAD Soluble WST-11 (Phase II trials). Eur Urol Focus. 2019;5:1022–8.
Taneja SS, Bennett J, Coleman J, Grubb R, Andriole G, Reiter RE, et al. Final results of a phase I/II multicenter trial of WST11 vascular targeted photodynamic therapy for hemi-ablation of the prostate in men with unilateral low risk prostate cancer performed in the United States. J Urol. 2016;196:1096–104.
Rees J, Patel B, MacDonagh R, Persad R. Cryosurgery for prostate cancer. BJU Int. 2004;93:710–4.
Durand M, Barret E, Galiano M, Rozet F, Sanchez-Salas R, Ahallal Y, et al. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer: focal cryoablation for unilateral low-risk prostate cancer. Bju Int. 2013;113:56–64.
Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. The “male lumpectomy”: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urologic Oncol Semin Orig Investig. 2008;26:500–5.
Mendez MH, Passoni NM, Pow-Sang J, Jones JS, Polascik TJ. Comparison of outcomes between preoperatively potent men treated with focal versus whole gland cryotherapy in a matched population. J Endourol. 2015;29:1193–8.
Shah S, Young HN, Cobran EK. Comparative effectiveness of conservative management compared to cryotherapy in localized prostate cancer patients. Am J Men’s Heal. 2018;12:1681–91.
Williams SB, Lei Y, Nguyen PL, Gu X, Lipsitz SR, Yu H-Y, et al. Comparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer. BJU Int. 2011;110:E92–8.
Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, et al. New and established technology in focal ablation of the prostate: a systematic review. Eur Urol. 2016;71:17–34.
Karagiannis A, Varkarakis J. Irreversible electroporation for the ablation of prostate cancer. Curr Urol Rep. 2019;20:63.
Collettini F, Enders J, Stephan C, Fischer T, Baur ADJ, Penzkofer T, et al. Image-guided irreversible electroporation of localized prostate cancer: functional and oncologic outcomes. Radiology. 2019;292:250–7.
Valerio M, Dickinson L, Ali A, Ramachadran N, Donaldson I, Mccartan N, et al. Nanoknife electroporation ablation trial: a prospective development study investigating focal irreversible electroporation for localized prostate cancer. J Urol. 2017;197:647–54.
Scheltema MJ, Chang JI, Bos W, van den, Gielchinsky I, Nguyen TV, Reijke TMde, et al. Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. Diagnostic Interventional Radiol Ank Turk. 2018;24:268–75.
Guenther E, Klein N, Zapf S, Weil S, Schlosser C, Rubinsky B, et al. Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments. Plos One. 2019;14:e0215093.
Peach MS, Trifiletti DM, Libby B. Systematic review of focal prostate brachytherapy and the future implementation of image-guided prostate HDR brachytherapy using MR-ultrasound fusion. Prostate Cancer. 2016;2016:1–13.
Kamrava M, Chung MP, Kayode O, Wang J, Marks L, Kupelian P, et al. Focal high-dose-rate brachytherapy: a dosimetric comparison of hemigland vs. conventional whole-gland treatment. Brachytherapy. 2013;12:434–41.
Graff P, Portalez D, Lusque A, Brun T, Aziza R, Khalifa J, et al. IDEAL 2a phase II study of ultrafocal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2018;102:903–11.
Morton G, McGuffin M, Chung HT, Tseng C-L, Helou J, Ravi A, et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020;146:90–6.
Maenhout M, Peters M, Moerland MA, Meijer RP, Bosch MAAJvanden, Frank SJ, et al. MRI guided focal HDR brachytherapy for localized prostate cancer: toxicity, biochemical outcome and quality of life. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2018;129:554–60.
Cosset J-M, Cathelineau X, Wakil G, Pierrat N, Quenzer O, Prapotnich D, et al. Focal brachytherapy for selected low-risk prostate cancers: a pilot study. Brachytherapy. 2013;12:331–7.
Chopra R, Colquhoun A, Burtnyk M, N’djin WA, Kobelevskiy I, Boyes A, et al. MR imaging–controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans. Radiology. 2012;265:303–13.
Chin JL, Billia M, Relle J, Roethke MC, Popeneciu IV, Kuru TH, et al. Magnetic resonance imaging–guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: a prospective phase 1 clinical trial. Eur Urol. 2016;70:447–55.
Capogrosso P, Ventimiglia E, Cazzaniga W, Montorsi F, Salonia A. Orgasmic dysfunction after radical prostatectomy. World J Men’s Heal. 2017;35:1–13.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Fallara, G., Capogrosso, P., Maggio, P. et al. Erectile function after focal therapy for localized prostate cancer: a systematic review. Int J Impot Res 33, 418–427 (2021). https://doi.org/10.1038/s41443-020-00357-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41443-020-00357-9
This article is cited by
-
Future directions in improving sexual function for prostate cancer patients
International Journal of Impotence Research (2021)